Safety and Impact on Quality of Life of Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Incidence and severity of device-related and procedure-related adverse events (AE)
研究概览
简要总结
The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
详细描述
The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy.
The secondary is to assess the impact on Quality of Life of Focused Ultrasound Bilateral and unilateral Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects. In addition, the impact of bilateral pallidotomy on motor development, pain perception, speech, memory, attention and cognition in these patients will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 8 Years 至 22 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The treating physician has chosen GPi-DBS or pallidotomy for the treatment of the secondary dystonia caused by cerebral palsy in this patient
- •Patient and/or legal representative, if the patient is underaged or not capable to give consent himself, have chosen pallidotomy as treatment
- •The consent to participate in the trial of the underaged patient, if he is capable to understand the study requirements, is required
- •Age at enrolment 8-22 years
- •Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury
- •Anti-dystonic pharmacotherapy insufficient
- •Stable anti-dystonic medication over the last 30 days
- •Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible)
- •No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention
- •Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study
- •Informed consent to take part in the study from patient and/or legal representative if the patient is underaged or not capable to give consent himself
- •Patient and/or legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
排除标准
- •Patients with known primary (e.g. DYT1) or idiopathic dystonia
- •Severe axial hypotonia with total loss of head control (e.g. absence of control at "upper thoracic level" in the SATCo score) (medication effect excluded)
- •Fixed hemi-dystonia
- •Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale >3)
- •Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention
- •Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.)
- •Condition likely to require use of MRI in the future
- •Any intracranial abnormality or medical condition that would contraindicate DBS surgery
- •Any findings in neuropsychological screening assessments that would contraindicate DBS surgery
- •Any current drug and / or alcohol abuse
- •Any history of frequent grand-mal seizures without response to anticonvulsive treatment
- •Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device.
- •The presence of DBS leads due the risks of these ferromagnetic devices in the MRI environment.
- •A history of neurostimulation intolerance in any area of the body.
- •Currently on any anticoagulant medications that cannot be discontinued during perioperative period.
- •Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <24 months.
- •Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator.
- •A female that is breastfeeding or of childbearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception ("antibaby-pill", hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent.
- •Subjects who have contraindications to anesthesia, in the judgment of the attending anesthesiologist
- •Subjects who are unwilling or unable to undergo general anesthesia
- •Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data.
- •Minimum head circumference < 49cm
- •Skull Density Ratio (SDR) <0.40.
研究组 & 干预措施
Focused Ultrasound Pallidotomy
Pediatric and young adult patients between ages of 8 and 22 years with pharmaco-resistant secondary dystonia due to dyskinetic cerebral palsy who have Focused Ultrasound Pallidotomy
干预措施: Focused Ultrasound Pallidotomy (Device)
结局指标
主要结局
Incidence and severity of device-related and procedure-related adverse events (AE)
时间窗: 2 years
Safety will be determined by an evaluation of the incidence and severity of device-related and procedure-related adverse events (AE) from the first treatment day visit through the 24-month post-treatment time point. All AEs will be reported and categorized as related to the device versus the ablation procedure.
次要结局
- Gross Motor Function Classification System (GMFCS)(2 years)
- Canadian Occupational Performance Measure (COPM)(2 years)
- Gross Motor Function Measure (GMFM-66)(2 years)
- Assessment of Cognition(2 years)
- Assessment of Attention(2 years)
- Tardieu Scale(2 years)
- Burke-Fahn-Marsden-Dystonia Rating Scale movement and disability(2 years)
- Family Scale (FaBel)(2 years)
- SF-36 for assessment of quality of life(2 years)
- Frenchay Dysarthria Assessment(2 years)
- Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD)(2 years)
- Wong Baker Faces(2 years)
- Strengths and Difficulties Questionnaire(2 years)
- Dyskinesia Impairment Scale (DIS)(2 years)
- Barry Albright Dystonia Scale(2 years)
- Assessment of cognition(2 years)
研究者
Chima Oluigbo
Principal Investigator and Sponsor
Children's National Research Institute